Enterin Overview
- Founded
- 2014

- Status
- Private
- Employees
- 17

- Latest Deal Type
- Series C
- Latest Deal Amount
- $14.2M

- Investors
- 3
Enterin General Information
Description
Developer of novel drugs intended to repair the dysfunctional gut-brain axis. The company's drugs displace α-synuclein aggregates and restore normal signaling between the gut and the brain, thereby improving the quality of life of patients with Parkinson's disease and other neurodegenerative conditions.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 2005 Market Street
- Suite 3125
- Philadelphia, PA 19103
- United States
Enterin Timeline
Enterin Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Later Stage VC (Series C) | 14-Sep-2020 | $14.2M | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
4. Debt - PPP | 28-Apr-2020 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
3. Early Stage VC (Series B) | 28-Jan-2019 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
2. Early Stage VC (Series A) | 10-Jul-2017 | $12.7M | $12.7M | 000.00 | Completed | Clinical Trials - Phase 2 |
1. Accelerator/Incubator | Completed | Startup |
Enterin Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A-2 | 1,865,223 | $0.000100 | 5% | $4.56 | $4.56 | 1x | $4.56 | 8.11% |
Series A-1 | 2,846,620 | $0.000100 | 5% | $2.91 | $2.91 | 1x | $2.91 | 12.38% |
Enterin Executive Team (7)
Enterin Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
Jay Brammer | Enterin | Chief Executive Officer & Board Member | 000 0000 |
Mark Finn | Scientia Ventures | Board Member | 000 0000 |
Michael Zasloff Ph.D | Enterin | Co-Founder, Chief Scientific Officer & Co-Chairman | 000 0000 |
Richard Propper MD | Self | Board Member | 000 0000 |
Richard Warburg Ph.D | Scientia Ventures | Board Member | 000 0000 |
Enterin Signals
Growth Rate

0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile

-35.5%.
530%
Size Multiple

219x
Median
Size Multiple
219x, 100th %ile

0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialEnterin Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Gibraltar Remembrance Services | Asset Manager | Minority | 000 0000 | 000000 0 | |
Scientia Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Science Center | Accelerator/Incubator | 000 0000 | 000000 0 |